Skip to main content
. 2020 Dec 21;27(2):183.e1–183.e7. doi: 10.1016/j.bbmt.2020.10.006

Figure 2.

Figure 2

Predicted preferred donor sources for adults (age ≥18 years) with acute myelogenous leukemia undergoing allogeneic HCT in 2023.